Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

NCT04982224 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Advanced NSCLC

Interventions

DRUG: REGN5093-M114
DRUG: Cemiplimab

Sponsor

Regeneron Pharmaceuticals